NCT06483295Recruiting
Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
Source: ClinicalTrials.gov · Last updated 28 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study focuses on the significant impact of lung cancer in China, highlighted by its high incidence and mortality rates, influenced by factors like aging populations, smoking, and environmental issues. It emphasizes the importance of understanding the duration, severity, and factors affecting post-surgery symptoms like pain and coughing in patients. The research underlines the value of patient-reported outcomes (PROs) in enhancing postoperative care and survival rates through improved symptom monitoring and patient engagement. Utilizing internet technology, specifically a platform integrated with WeChat, the study aims to improve patient management and follow-ups post-discharge. The objective is to use mobile internet technology to build a high-quality prospective database on postoperative lung cancer patient outcomes, analyzing factors affecting postoperative discomfort and assessing the role of interactive platforms in improving patient care.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 216 (estimated)
- First submitted
- 13 Mar 2024
- Start date
- 24 Mar 2024
- Primary completion date
- 7 Jul 2024
- Lead sponsor
- Shanghai Chest Hospital
- Diseases
- Lung cancer
- NCT number
- NCT06483295
What you commit to
- Study type: Interventional
- Planned participants: 216
- From 24 Mar 2024 to the primary completion date, 7 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received any non-surgical anti-tumour therapy (radiotherapy, chemotherapy, targeted therapy or immunotherapy) for lung cancer during the follow-up period.
- After enrolment, preoperative emergence of serious comorbidities (inability to tolerate surgery or anaesthesia) that are not suitable for, or cannot be implemented as planned, in the study's treatment regimen.
Other illness
- After admission, the patient's condition changes and the need to change from elective surgery to emergency surgery is confirmed by the doctor in charge.
Other
- At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.
Who the study is looking for
- Diagnosed with Stage I-III lung cancer and surgically resected at our centre.
- Owns and uses a smartphone and can use WeChat.
- Volunteer to participate in this study and sign an informed consent form.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zuodong Song Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
Related publications
- Patient-reported outcomes with a personalized follow-up program after lung cancer resection: A single-center randomized controlled trial.Asia Pac J Oncol Nurs · 2026 · PMID 41625083
This page is information, not medical advice. Discuss any trial with your doctor.